DIFICLIR significantly reduces recurrence and mortality when used first-line in patients with CDI
Data presented from the CDI Service Evaluation study shows that the adoption pattern of treatment impacts CDI outcomes. Compared to traditional broad-spectrum antibiotics, first-line use of fidaxomicin, a targeted treatment, in all CDI patients provides improved outcomes in terms of recurrence rate, all-cause mortality and cost effectiveness, compared to use in selected patients only. (8) CDI is associated with high-mortality (5,6,7) and cost burden, (9) therefore reducing the incidence and recurrence of CDI is a priority for clinicians, payers and health authorities alike. (Source: Pharmacy Europe)
Source: Pharmacy Europe - May 19, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Association News Practical therapeutics Cost effectiveness Industry News Infectious Disease broad-spectrum antibiotics cdi DIFICLIR fidaxomicin Latest News Source Type: news
A need for global awareness of the burden of psoriatic arthritis
In conjunction with the opening of the 68th World Health Assembly, the International Federation of Psoriasis Associations, IFPA, launches an issue brief on psoriatic arthritis, calling the international community to action. (Source: Pharmacy Europe)
Source: Pharmacy Europe - May 18, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Association News Other conferences & symposia Dermatology Rheumatology eular IFPA international federation of psoriasis associations Latest News psoriatic arthritis world health assembly Source Type: news
UKCPA Events in June and July 2015
16 June
Update on the treatment of type II diabetes
UKCPA Diabetes and Endocrinology Group
To view the event flyer, please see here: UKCPA Diabetes and Endocrinology Group Masterclass Information Flyer.
This event has secured further industry sponsorship and the fee will be reduced SOON.
Kingsway Hall Hotel, London. For venue location and travel information, please click here: http://www.kingswayhall.co.uk/contact-en.html. (Source: Pharmacy Europe)
Source: Pharmacy Europe - May 15, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor ' s Pick UK Conference and Symposia Latest News ukcpa Source Type: news
New test could identify resistant tuberculosis faster in London
This could help health service providers to better treat disease, control transmission of this infection, and monitor outbreaks. Tuberculosis (TB) disease rates in some parts of London are as high as in Sub-Saharan Africa, and drug-resistant strains are becoming increasingly common. These require specific treatments, and if doctors know that a bug is resistant they can start therapy earlier, often leading to better outcomes. (Source: Pharmacy Europe)
Source: Pharmacy Europe - May 11, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Industry News Infectious Disease diagnostics infection control Latest News Mtb tuberculosis Source Type: news
Early treatment and a longer life - new Orfadin formats meet new patient needs
Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the oral suspension formulation and the 20mg capsule of Orfadin (nitisinone) for the treatment of hereditary tyrosinaemia type-1 (HT-1). HT-1 is a rare genetic disease that affects infants and children; it is progressive in nature, may result in liver and kidney failure and can be fatal if untreated. (Source: Pharmacy Europe)
Source: Pharmacy Europe - May 6, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Legislation & regulation Hepatic disorders Nephrology chmp EMA genetic disease hereditary tyrosinaemia type-1 HT-1 Latest News nitisinone oral suspension orfadin paed Source Type: news
Data presented at ARVO 2015 further showcase the real-world efficacy of EYLEA® in UK clinical practice
Bayer HealthCare reports that real-world data from a UK wide National Aflibercept Audit and Moorfields Aflibercept Audit have been presented at The Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting showcasing the efficacy of EYLEA® (aflibercept solution for injection) for the treatment of wet age-related macular degeneration (wAMD). The results from both audits highlight that treatment with aflibercept in NHS clinical practice has resulted in stabilised or improved visual and/or anatomical outcomes in treatment-naïve and pre-treated patients; (1–4) reflecting the results seen in the pivota...
Source: Pharmacy Europe - May 5, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Association News Clinical trials Practical therapeutics Industry News Other conferences & symposia Ophthalmology aflibercept ARVO 2015 EYLEA Latest News VIEW clinical trial wAMD wet age-related macular degen Source Type: news
Novel approaches to fight infections presented at pipeline corner
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) announced breaking developments in the global fight against infections – with new mechanisms and approaches presented by smaller companies in a dedicated pipeline session at the annual congress (ECCMID) in Copenhagen. (Source: Pharmacy Europe)
Source: Pharmacy Europe - April 29, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick European Conferences and Symposia Practical therapeutics Industry News Drug development Drug discovery Infectious Disease Conference reports Research antibacterial antimicrobial Beam Alliance Centre for Anti-Infec Source Type: news
Genmab announces Phase III study of Arzerra® met primary endpoint in patients with relapsed CLL
Genmab A/S announced that the top-line results from the Phase III COMPLEMENT 2 study showed that treatment with Arzerra® (ofatumumab) plus fludarabine and cyclophosphamide met the primary endpoint of improved progression-free survival (PFS) in patients with relapsed CLL (p=0.0036) compared to those given fludarabine and cyclophosphamide alone. The safety profile observed in this study was consistent with other trials of ofatumumab and no new safety signals were observed. (Source: Pharmacy Europe)
Source: Pharmacy Europe - April 28, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Drug development Therapeutic drug monitoring Legislation & regulation Oncology Patient care Research arzerra COMPLEMENT 2 study cyclophosphamide fludarabi Source Type: news
RGU Pharmacy students highlight treatments for allergic reactions
RGU’s Institute for Healthcare Improvement (IHI) Student Chapter held an Anaphylaxis Event at the university’s Riverside East building at the end of March. Anaphylaxis is a severe, potentially life-threatening allergic reaction that can develop rapidly. The event was organised to increase awareness of which prescription only medicines pharmacists are legally permitted to supply and administer without prescription in life saving situations. (Source: Pharmacy Europe)
Source: Pharmacy Europe - April 27, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Association News UK Conference and Symposia Patient care allergic reactions anaphylaxis Latest News robert gordon university Source Type: news
New treatment for rare forms of leukaemia available across Scotland
ARIAD today welcomed the Scottish Medicine Consortium’s (SMC) acceptance to use Iclusig® (ponatinib) as a clinical and cost effective treatment for all phases of chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), in accordance with Iclusig’s licenced indication. (Source: Pharmacy Europe)
Source: Pharmacy Europe - April 27, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Haematology Oncology Patient care chronic myeloid leukaemia Latest News philadelphia chromosome positive ponatinib Source Type: news
Sobi supports children with haemophilia to talk about their disease - introduces movie maker app
Sobi has therefore, with the support of Consultant Nurse Dr Kate Khair and her team at the Great Ormond Street Hospital for Children, developed the Magic Movie Maker, which is now being introduced in the UK – a free iPad app created to enable children to enlighten others about what it means to live with haemophilia. (Source: Pharmacy Europe)
Source: Pharmacy Europe - April 23, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Haematology children with haemophilia GOSH great ormomd street iPad app Magic movie maker patient support Sobi Source Type: news
New European trial initiated to identify response to talimogene laherparepvec using intratumoural CD8+ T lymphocytes as biomarker
Amgen announced the initiation of a clinical trial, NCT02366195, to determine whether baseline CD8+ T lymphocytes density is a biomarker of response to talimogene laherparepvec, an investigational oncolytic immunotherapy, in patients with unresected stages IIIB to IV melanoma. The first subject has enrolled into the study, with the goal of including approximately 110 patients across 49 clinical trial sites in 11 different countries in Europe. (Source: Pharmacy Europe)
Source: Pharmacy Europe - April 23, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Oncology intratumoural CD8 T lymphocytes Latest News melanoma stage IIIB Source Type: news
Antibiotic Armageddon in UK and Europe by 2025
The European Society of Clinical Microbiology and Infectious Disease (ESCMID) – an organisation that explores risk assessment, knowledge sharing and best practices in the fight against infectious disease – has warned that Britain and Europe collectively could face more than a million deaths in an impending "Antibiotic Armageddon” unless more is done to develop new cures, rapid diagnostics and preventative measures to combat the spread of drug resistant diseases. (Source: Pharmacy Europe)
Source: Pharmacy Europe - April 21, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Association News Clinical trials European Conferences and Symposia Practical therapeutics Therapeutic drug monitoring Drug discovery Patient safety Infectious Disease Patient care Policy & practice Research 20 Source Type: news
Pfizer and Pharmacy Voice launch campaign encouraging the public to make effective use of local NHS services
A new version of the Right Route: Right Care campaign launched today by Pfizer Healthy Partnerships (PHP) with endorsement from Pharmacy Voice, aims to support pharmacy teams in encouraging the public to make the most effective use of their local NHS services, using a simple traffic light system. (Source: Pharmacy Europe)
Source: Pharmacy Europe - April 9, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Patient safety Patient care Policy & practice healthcare advice Latest News nhs services Pfizer Healthy Partnership Pharmacy Voice traffic light system Source Type: news
Post-hoc analyses extend understanding of the efficacy and safety of lurasidone
Takeda Pharmaceuticals International GmbH and Sunovion Pharmaceuticals Inc. announced the results from three post-hoc analyses evaluating the efficacy and safety of Latuda® (lurasidone) in patients with schizophrenia at the 23rd European Congress of Psychiatry (EPA). The analyses suggest that lurasidone is associated with reduced hostility in patients with schizophrenia and reduced frequency of certain adverse events commonly associated with antipsychotic treatment. (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 31, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials European Conferences and Symposia Practical therapeutics Industry News Neurology Psychiatry Patient care Research antipyschotic treatment. PANSS EPA Latest News lurasidone prolactin levels schi Source Type: news
